EpiFix
-
Biologics
MiMedx To Present Clinical And Scientific Studies At Desert Foot Conference
MARIETTA, Ga., Nov. 6, 2018 /PRNewswire/ — MiMedx Group, Inc. (NASDAQ: MDXG), a leading developer and marketer of regenerative and therapeutic biologics, today…
Read More » -
Biologics
MiMedx Announces Statistically Significant Results In New Multicenter Clinical Study Of Healing Of Diabetic Foot Ulcers Using EpiFix®
MARIETTA, Ga., Aug. 24, 2018 /PRNewswire/ — MiMedx Group, Inc. (NASDAQ : MDXG ), a leading developer and marketer of regenerative and therapeutic biologics, today…
Read More » -
Biologics
MiMedx Provides Update On Its Reimbursement Coverage
MARIETTA, Ga., Nov. 21, 2017 /PRNewswire/ — MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic…
Read More » -
MiMedx EpiFix® Receives Coverage From Kaiser Permanente
MARIETTA, Ga., May 4, 2017 /PRNewswire/ — MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative biologics…
Read More » -
Biologics
MiMedx to Present at the European Wound Management Association Annual Conference
MARIETTA, Ga., April 24, 2017 /PRNewswire/ — MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative…
Read More » -
Biologics
MiMedx EpiFix Receives Coverage From Aetna
MARIETTA, Ga., Dec. 27, 2016 /PRNewswire/ — MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected…
Read More » -
Extremities
Grafix Demonstrates Superior Clinical Outcomes Compared with EpiFix in “Real World” Study
COLUMBIA, Md.–(BUSINESS WIRE)–Osiris Therapeutics, Inc. (NASDAQ: OSIR), a leading cellular and regenerative medicine company, focused on developing and marketing products…
Read More » -
Hospitals
MTF Receives Favorable Ruling from the Patent Trial and Appeal Board in Patent Dispute with MiMedx
EDISON, N.J., Aug. 25, 2015 /PRNewswire/ — The Musculoskeletal Transplant Foundation (MTF) announced today the Patent Trial and Appeal Board (“PTAB”) has ruled…
Read More » -
Hospitals
MiMedx Group (MDXG) Announces Favorable PTAB Ruling for EpiFix and AmnioFix Patents
MiMedx Group, Inc. (NASDAQ: MDXG) announced today the Patent Trial and Appeal Board (“PTAB”) has ruled in favor of the Company’s…
Read More » -
Recon
MiMedx Receives 2015 Innovative Technology Award from Novation
MARIETTA, Ga., May 8, 2015 /PRNewswire/ — MiMedx Group, Inc. (NASDAQ:MDXG), the leading regenerative medicine company utilizing human amniotic tissue and…
Read More »